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Abstract
Background: Neopterin, a biomarker of macrophage activation, is elevated in the cerebrospinal fluid (CSF) of most
HIV-infected individuals and decreases after initiation of antiretroviral therapy (ART). We studied decay characteristics
of neopterin in CSF and blood after commencement of ART in HIV-infected subjects and estimated the set-point
levels of CSF neopterin after ART-mediated viral suppression.
Methods: CSF and blood neopterin were longitudinally measured in 102 neurologically asymptomatic HIV-infected
subjects who were treatment-naïve or had been off ART for ≥ 6 months. We used a non-linear model to estimate
neopterin decay in response to ART and a stable neopterin set-point attained after prolonged ART. Seven subjects
with HIV-associated dementia (HAD) who initiated ART were studied for comparison.
Results: Non-HAD patients were followed for a median 84.7 months. Though CSF neopterin concentrations
decreased rapidly after ART initiation, it was estimated that set-point levels would be below normal CSF neopterin
levels (<5.8 nmol/L) in only 60/102 (59%) of these patients. Pre-ART CSF neopterin was the primary predictor of
set-point (P <0.001). HAD subjects had higher baseline median CSF neopterin levels than non-HAD subjects
(P <0.0001). Based on the non-HAD model, only 14% of HAD patients were predicted to reach normal levels.
Conclusions: After virologically suppressive ART, abnormal CSF neopterin levels persisted in 41% of non-HAD and
the majority of HAD patients. ART is not fully effective in ameliorating macrophage activation in CNS as well as
blood, especially in subjects with higher pre-ART levels of immune activation.
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Introduction
Neopterin is a low-molecular weight pteridine (253 Dalton),
predominantly produced by macrophages and related cells
after stimulation with IFN-γ [1], which serves as a sensitive
marker of activation of these cells. Cerebrospinal fluid
(CSF) neopterin is produced principally within the central
nervous system (CNS), reflecting mainly activation of CNS
macrophages and other cells of the monocytic lineage, and
is elevated in a number of infectious and inflammatory
neurological diseases, including HIV-infection [2-6].
CSF levels of neopterin are elevated throughout the
course of HIV infection with highest values occurring in
patients with HIV-associated dementia (HAD) and
opportunistic CNS infections [7,8]. In patients with HAD,
levels of CSF neopterin have also been shown to correlate
with the severity of the dementia [9]. After commence-
ment of combination antiretroviral therapy (ART), CSF
neopterin decreases markedly, but remains mildly above
normal levels in a substantial number of patients despite
several years of receiving ART [10,11]. Even patients with
systemic virological failure exhibit a substantial reduction
of CSF neopterin concentrations, though above that of
virologically suppressed patients [12].
In this present study, we have analyzed the decay cha-
racteristics of neopterin in CSF and blood in HIV-infected
individuals initiating combination ART. We wanted to
estimate the proportion of subjects with persistently
elevated intrathecal immune activation after long-term
treatment, and more particularly, to determine which* Correspondence: aylin.yilmaz@gu.se1Department of Infectious Diseases, University of Gothenburg, Journalvagen
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In this retrospective study, we used stored CSF and blood
specimens from two clinical centers in Gothenburg,
Sweden, and San Francisco, USA. All patients who had
undergone at least one lumbar puncture prior to initiation
of combination ART and at least one lumbar puncture on
treatment were considered for this study. Participants
were either ART-naive or had been off treatment for ≥6
months at ART initiation (baseline). Because this study fo-
cused on neopterin concentrations among virologically
suppressed patients, only subjects with viral suppression
after initiation of ART were included. Virological suppres-
sion was defined as CSF and plasma HIV RNA levels <50
copies/mL within 6 months from the start of therapy, or if
followed for a shorter period, >2 log10 reduction of the
viral load. Patients with virologic failure, defined as two
consecutive plasma samples with HIV RNA >50 copies/
mL after 6 months of ART, were excluded. Decay and set-
point models were based on a group of neurologically
asymptomatic individuals fulfilling the above criteria. A
small group of patients with HAD was also studied for
comparison. All subjects were studied within study proto-
cols approved by the Research Ethics Committee of the
University of Gothenburg or the University of California
San Francisco Committee on Human Research.
Methods
Neopterin was measured by a commercially available
radio-immunoassay or enzyme-linked immunosorbent
assay (Neopterin RIA and EIA, BRAHMS, Hennigsdorf,
Germany) [13]. The same antibodies are used in these
two assays, and the results are interchangeable [14].
Normal neopterin reference values were <8.8 nmol/L in
blood and <5.8 nmol/L in CSF [4,13,15]. HIV-1 RNA
in CSF and plasma was measured using the Roche
Amplicor assay (version 1.5, Hoffman-La Roche, Basel,
Switzerland). The assay has a lower detection limit of
20 copies/mL (1.30 log10 copies/mL). All HIV-1 RNA
values <20 copies/mL were set as 19 copies/mL. The
CD4+ T-cell count was analyzed by flow cytometry in
local clinical laboratories.
Statistical analysis
Descriptive statistics were generated for all variables
involved in the analyses. Comparisons of continuous
statistical measures between the non-HAD and HAD
patients were performed using the Kruskal-Wallis test.
We used non-linear mixed models to reflect the decay
characteristics of both CSF and blood neopterin levels
after initiation of ART. From previously published
reports [16,17] we assumed that CSF and blood neop-
terin levels would decay rapidly after initiation of treat-
ment, and would stabilize after some time reaching a
set-point. The model used for both the CSF and blood
neopterin levels is given by the following equation:
yij ¼ β0 þ u0i þ β1Xi þ β2 þ u2i þ β3Xi
 




where yij corresponds to neopterin levels for each subject
and post-baseline study visit, tij, Xi is the log-transformed
pre-treatment blood or CSF (log-transformed) neopterin
levels, β0, β1, govern the association between follow-up
CSF or blood neopterin levels overall and with baseline
levels respectively, β2 and β3 estimate the reduction in
CSF or blood neopterin levels from baseline to the set-
point levels after prolonged treatment, overall and associ-
ated with baseline levels, and β4 and β5 determine the rate
of decay overall and according to the pre-treatment
neopterin levels respectively. Subject-specific random
effects u0i and u2i were added to allow initial and set-point
neopterin levels to vary for each patient. The impact of
the pre-treatment neopterin level on the post-baseline
visits, the ultimate set-point reached, and the rate of decay
of neopterin levels were tested using the Wald test, invol-
ving the coefficients β1, β3, and β5 respectively. The size
and sign of the model coefficients is interpreted as follows:
an estimate β1 >0 implies a positive association between
pre-treatment and post-treatment neopterin levels. The
estimated set-point is (β0 + β2) + (β1 + β3)Xi. This suggests
that an estimate β1 + β3 >0 implies that patients with
higher pre-treatment CSF neopterin levels would end up
with a higher set-point, while if β1 + β3 <0 the exact
opposite is concluded. In addition, β5 >0 implies a decay
rate associated with baseline CSF neopterin levels that is
faster than the average rate of decay, which is estimated
by β4, while β5 <0 suggests that higher baseline neopterin
levels are associated with slower rates of decay. Other
models involving factors potentially associated with long-
term neopterin levels were also considered. They included
longitudinally measured HIV RNA levels in the CSF and
plasma and CD4+ T-cell counts at the start of therapy. In
the presence of pre-treatment neopterin levels, no other
factors were found to be significantly associated with
long-term CSF or blood neopterin levels, so the model de-
scribed above was used.
In addition to producing point estimates of the neopterin
set-point for each subject, we tested whether the estimated
set-point corresponding to the median and third quartile
levels of baseline CSF and blood neopterin in the neuro-
logically asymptomatic population was significantly higher
than the upper limit of normal using the Wald chi-square
test. This test compares the difference between the upper
limit of normal from the estimated neopterin set-point
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scaled by the variance of the estimate, and provides a cri-
terion for deciding whether this difference is large enough
to be considered statistically significant. Using the model
developed for the neurologically asymptomatic patients,
we also tested whether the estimated CSF and blood
neopterin set-point corresponding to the median and third
quartile levels of baseline CSF and blood neopterin among
subjects with HAD was significantly higher than the upper
limit of normal of CSF and blood neopterin levels in the
same manner. All analyses were performed with R version
2.11.1 (The R Foundation for Statistical Computing).
Results
Patients
In total, 102 chronically HIV-1-infected individuals with-
out neurological symptoms fulfilled the inclusion criteria
and were included in the study (88 from Gothenburg
and 14 from San Francisco) between 1996 and 2009. All
neurologically asymptomatic subjects were initiated on
combination ART with a median CNS penetration ef-
fectiveness (CPE) score of 8 (range 5 to 13) [18]. As a
comparison group, seven subjects with HAD (one from
Gothenburg and six from San Francisco) were analyzed
separately and compared to the non-HAD group. They
initiated ART with a median CPE score 9 (range 6 to
13). Subject baseline characteristics are presented in
Table 1. Baseline was defined as the closest time point
prior to ART initiation. This ranged from 0 to 36 weeks
prior to the start of therapy, with a median value of 0.7
weeks. The number of evaluations and the extent of
follow-up varied among the subjects. In the non-HAD
group median follow-up was 84.7 months compared to
21.6 months among the HAD subjects (log-rank P =
0.017). The two patient groups were similar with respect
to age, sex, CD4+ T-cell count, and plasma HIV RNA
levels at baseline. CSF HIV RNA and neopterin levels
were significantly higher among HAD-patients than
non-HAD subjects (P = 0.001).
The neurologically asymptomatic subjects stayed asymp-
tomatic during the whole study period, but structured
neuropsychological testing was not performed. All seven
HAD-patients improved functionally after initiation of
ART. Neuropsychological testing was performed in six
HAD-patients. Four of these improved substantially. One
got worse and one remained about the same on testing.
The average change in NPZ-4 NPZ (composite neuro-
psychological test Z score) score was 1.8 (improved) with
SD of 2.3.
CSF neopterin levels
The median pre-treatment CSF neopterin level for the 102
neuroasymptomatic subjects was 19.9 nmol/L (range 4.0 to
138.0). Individual and overall average CSF neopterin decay
trajectories for these patients are presented in Figure 1.
Forty-two out of the 102 neuroasymptomatic patients
(41%) had estimated set-point CSF neopterin levels that
were higher than the upper limit of normal (5.8 nmol/L).
The estimated model of CSF neopterin decay was:
yij ¼ −50:85þ 21:97Xi þ 46:07−18:67Xi
1− exp − exp −13:62þ 2:72Xið Þtij
  
All coefficients were significantly different from zero
(P-value <0.0001 in all cases). The model (see Methods) is
interpreted as follows: subjects with higher pre-treatment
CSF neopterin levels were expected to have higher set-
points compared to subjects with lower baseline levels
because of the positive sum of pre-treatment and post-
treatment coefficients (β1 + β3=3.3). This means that
a subject with a one-log higher pre-treatment CSF
neopterin level compared to another subject would be
expected to have a set-point 3.3 nmol/mL higher. Con-
versely, subjects with pre-treatment CSF neopterin at the
third quartile (33 nmol/mL) are estimated to have a 1.72
nmol/mL higher set-point compared to subjects with
pre-treatment CSF neopterin levels near the median
(19.6 nmol/mL). In addition, subjects with higher pre-
Table 1 Subject characteristics
Characteristic non-HAD (n = 102) HAD (n = 7) P-value*
Sex (male), number (%) 101 (99) 6 (86) 0.0125
Age, years 41 (18, 68) 46 (30, 58) 0.184
CD4 cell count (×106 cells/L) 190 (0, 630) 138 (53, 344) 0.711
CPE score 8.0 (5.0, 13.0) 9.0 (6.0, 13.0) 0.060
CSF neopterin (nmol/L) 19.6 (4.0, 138.0) 54.4 (13.7, 154.0) 0.001
Blood neopterin (nmol/L) 21.7 (6.8, 77.0) 25.0 (12.0, 28.9) 0.359
CSF HIV RNA (log10 copies/mL) 3.93 (1.28, 6.26) 5.08 (3.08, 5.98) 0.015
Plasma HIV RNA (log10 copies/mL) 5.05 (1.28, 6.89) 5.31 (4.68, 5.61) 0.277
Follow-up, weeks 84.7 (0.4, 682.7) 21.6 (4.1, 150.0) 0.017
Values are presented as median (range) unless stated otherwise. *Fischer exact test for categorical gender, Kruskal-Wallis test for continuous factors, and log-rank
test for the length of follow-up. HAD, HIV-associated dementia; CPE: central nervous system penetration effectiveness; CSF, cerebrospinal fluid.
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treatment CSF neopterin levels experienced faster rates
of decay than subjects with lower pre-treatment CSF
neopterin levels as suggested by the positive sign of coeffi-
cient β5 >0 There was no association between pre-
treatment CD4+ T-cell count or HIV RNA levels in CSF
or blood with follow-up CSF neopterin levels, so these fac-
tors were excluded from any further consideration in the
analyses.
Blood neopterin levels
The median pre-treatment blood neopterin level in non-
HAD subjects was 21.7 nmol/L (range 6.8 to 77.0)
(Table 1). The median blood neopterin level among
HAD subjects was 25.0 nmol/L (range 12.0 to 28.9),
which was not significantly different from non-HAD
patients (P = 0.359). An identical analysis to the one
presented for CSF neopterin levels was carried out with
respect to blood neopterin levels. The model fitted was:
yij ¼ −68:13þ 27:78Xi þ 74:77−27:00Xi
1− exp − exp 1:03þ 0:32Xið Þtij
  
Pre-treatment blood neopterin levels constituted the
only factor significantly associated with post-treatment
levels (P <0.0001). Subjects having higher pre-treatment
levels were estimated to have higher set-point levels as
implied by the sum of the coefficients β1 + β3 = 0.78. In
contrast to the CSF neopterin model, baseline blood
neopterin levels were weakly associated with the rate of
decay after initiation of ART estimated by β5 (P = 0.091).
That is, blood neopterin levels decreased in uniform
fashion for all patients with those having the highest blood
neopterin levels decreasing slightly more slowly.
It was estimated that 28 out of 102 (27%) non-HAD
subjects and 6 out of 7 (86%) HAD-subjects had blood
neopterin set-point levels above the upper limit of normal.
This is seen from the individual and overall trajectories
presented in Figure 2.
Discussion
Neopterin is a very sensitive marker of macrophage acti-
vation, and serum and urine levels of neopterin were
used in the beginning of the HIV epidemic to convey
prognostic information about disease progression [19].
Elevated CSF levels of neopterin are found throughout
the course of HIV infection with the highest levels
occurring in patients with HAD and opportunistic infec-
tions [4,20,21]. In patients with HAD, levels of CSF
neopterin have also been shown to correlate with the se-
verity of the dementia [9]. Almost all of the neopterin
detected in the CSF originates from inside the CNS, and
elevated levels of CSF neopterin indicate activation of
CNS macrophages and other cells of the monocytic
lineage within this compartment [21]. Due to these
features, CSF neopterin is a useful biomarker of HIV
CNS disease [8,22,23]. Although it was not the main
objective of this study, the baseline patient characteris-
tics are in line with previous results, with HAD patients
having significantly higher pre-treatment CSF neopterin
levels than the asymptomatic subjects (median, 54.4 ver-
sus 19.6 nmol/L).
It is well established that combination ART has a pro-
found effect on CSF HIV RNA and neopterin levels
Figure 1 Plot of observed data (circles), individual
cerebrospinal fluid (CSF) neopterin decay curves (hashed grey
lines) after initiation of antiretroviral therapy (at week 0) and
average decay rate (solid orange curve).
Figure 2 Plot of observed data (circles), individual blood
neopterin decay curves (hashed grey lines) after initiation of
antiretroviral therapy (at week 0) and average decay rate (solid
orange curve).
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[24,25]. Previous studies have demonstrated that a sig-
nificant proportion of patients have signs of ongoing
macrophage activation inside the CNS, even after several
years of effective treatment. In one study, 60% of the
participants had elevated CSF neopterin levels after four
years on suppressive combination ART [10,11]. The
findings of the present study are in concordance with
these previous results; 41% (42/102) of the neuro-
asymptomatic patients were estimated to reach CSF
neopterin set-point levels above the normal range des-
pite suppressive ART. These 42 subjects had the highest
pre-treatment CSF neopterin levels. All patients in this
study that were followed for at least six months on ART
were suppressed (<50 copies/mL) in plasma and CSF.
Thus, the ongoing immune activation, observed in such
a large proportion of successfully treated patients, might
be attributable to low-level persistent viral replication
within the CSF or the brain.
In patients on combination ART, the lowest CSF
neopterin levels have been found in patients with the
lowest CSF viral loads (<2.5 copies/mL) [26]. This would
support the idea that viral replication within or close to
the CSF, at least to some extent, is partly driving the
inflammatory response. It has also been suggested that
an inflammatory response, once triggered, may lead to a
self-sustaining state of cellular activation [27], as has
been seen in patients with herpes simplex virus type-1
encephalitis [28]. Findings in this study are consistent
with these reports. HIV RNA levels measured in CSF or
plasma were not significantly associated with CSF
neopterin trajectories (analyses not shown). In addition,
all study participants had experienced virologic control
to the limit of standard detection as a result of their
treatment and CSF neopterin levels were the only factor
strongly associated with subsequent decay rates and the
ultimate set-point levels.
Estimated blood neopterin set-point levels remained
higher than 8.8 nmol/L (the upper limit of normal blood
neopterin levels) in 27% (28/102) of non-HAD patients
(Figure 2) and 86% of HAD patients. Pre-treatment
blood neopterin levels were the only factor strongly
associated with set-point levels. Subjects with higher
pre-treatment CSF neopterin levels were estimated to
have higher set-point levels.
The decision to exclude the seven patients with HAD
from the overall estimation of CSF and blood neopterin
decay rates was made because this small number of
patients makes it difficult to draw any definitive conclu-
sions about this group. In addition, six of the seven HAD
patients were from the same site potentially confounding
the results. For this reason, all statements and compari-
sons between HAD and non-HAD patients are intended
for hypothesis generating purposes. Not unexpectedly, the
seven patients with HAD had significantly higher CSF
HIV RNA and neopterin levels at baseline compared to
the remaining subjects (Table 1). By virtue of having
higher baseline CSF neopterin levels, and using the statis-
tical model fit to the non-HAD subject data, HAD
subjects would be expected to have higher set-point levels
as well. The observation that most HAD patients would
experience prolonged immune activation even after
long-term administration of ART is consistent with the
hypothesis that patients with HAD have a more compart-
mentalized HIV-infection within CNS macrophages,
whereas infection in non-HAD patients may be largely
transitory, non-compartmentalized, and supported within
lymphocytes and with less marked activation of macro-
phages [29]. Indeed, we cannot rule out that the high
baseline CSF neopterin and elevated set-point CSF
neopterin levels in some of the neuroasymptomatic pa-
tients may indicate early, subclinical HIV-encephalitis.
There are a number of limitations with the present
study. The most important one is related to the strong
structure imposed by the model, where neopterin levels
are assumed to remain constant once the set-point is
reached. The model thus does not allow for an increase
of CSF neopterin levels (which would suggest a re-
emergence of immune activation) or a decrease in the
levels after additional time receiving ART. In addition,
based on the imposed structure and, borrowing informa-
tion from the other patient observations, the model
predicts the likely set-point in some of the subjects who
did not have sufficient follow-up to have reached it. This
concern applies mainly to HAD patients, who had
shorter follow-up. However, data from these subjects
had no impact on the final model as they were excluded
from the model generation. To address any possibility
that our results are artifacts of model-imposed structure,
we have performed extensive goodness-of-fit reviews of
the model. In addition, even among patients with very
long follow-up, we have not detected unequivocal
evidence of increasing or decreasing neopterin levels
after the set-point was reached. A final limitation has to
do with applying the results of a model, which was
developed in the non-HAD cohort, to the HAD patients.
For this reason, observations obtained from the HAD
cohort must be interpreted cautiously and should be
replicated in a larger study.
Despite these limitations, the present study raises sig-
nificant concerns about the possible long-term risks for
neurological complications in HIV-infected individuals.
The subjects in the present study were not routinely ex-
amined with neuropsychological testing, but they did
not develop any clinical signs of progressive neurological
symptoms during the study period. However, the long life
expectancy of HIV-infected individuals and the neuro-
logical insults that come with older age in combination
with a persistent immune activation might in the long run
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contribute to significant functional neurological impair-
ment. Even though we know that many HIV-infected
individuals have signs of ongoing immune activation in
the CNS, we do not know what the clinical implications of
this are. Chronic inflammation and immune stimulation
is regarded as harmful in the long run in many other dis-
eases, such as arteriosclerosis, ulcerous colitis, and chronic
infectious and non-infectious hepatitis. It is therefore not
difficult to imagine the possible devastating effects of
having an active immune system enclosed in a protected,
immunologically distinct compartment such as the CNS.
Intrathecal immune activation seems to continue
despite long-term treatment with effective ART, albeit at
lower levels than without treatment, underlining the
possible limitations of ART in completely mitigating the
neurological impact of the virus even among virologic-
ally suppressed individuals.
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